Showing 1171-1180 of 2676 results for "".
- Fenfluramine May Usher in Higher Standards for Treatment of Dravet Syndromehttps://practicalneurology.com/news/fenfluramine-may-usher-in-higher-standards-for-treatment-of-dravet-syndrome/2469642/In an editorial in Epilepsy and Behavior, Helen Cross, MD and Joseph Sullivan, MD suggest fenfluramine (Fintepla; Zogenix, Emeryville, CA) clinical trial results can raise the bar for efficacy of antiseizure medications (ASMs) for
- Peanut Consumption May Lower Risk of Strokehttps://practicalneurology.com/news/peanut-consumption-may-lower-risk-of-stroke/2469686/According to new research published in Stroke, people living in Japan who ate peanuts (on average 4-5 peanuts/day) had a lower risk of ischemic stroke or a cardiovascular disease event. Previous studies have l
- Award Recipients Recognized at the 2024 International Congress of Parkinson’s Disease and Movement Disordershttps://practicalneurology.com/news/award-recipients-recognized-at-the-2024-international-congress-of-parkinsons-disease-and-movement-disorders/2470598/The International Parkinson’s Disease and Movement Disorders Society (MDS) has announced recipients of the 2024 MDS Awards. The awards honor professionals in the field who are elevating care for movement disorders through their contributions to research, scholarship, and clinical work. The
- FDA Approves Mirabegron for Neurogenic Detrusor Overactivity in Pediatric Patientshttps://practicalneurology.com/news/fda-approves-mirabegron-for-neurogenic-detrusor-overactivity-in-pediatric-patients/2469543/The Food and Drug Administration approved a new indication for mirabegron extended-release tablets (Myrbetriq; Silver Spring, MD) and mirabegron for extended-release oral suspension (Myrbetriq Granules; Silver Spring, MD) to treat neurogenic detrusor overactivity (NDO) in children age 3 yea
- Experimental BTK Inhibitor Suppressed Inflammatory Disease Activity in Those with Relapsing MShttps://practicalneurology.com/news/long-term-treatment-with-fenebrutinib-suppressed-inflammatory-disease-activity-in-relapsing-ms/2473796/Fenebrutinib (Roche, Basel, Switzerland), an investigational oral, reversible noncovalent Bruton tyrosine kinase (BTK) inhibitor, demonstrated significant efficacy in suppressing inflammatory disease activity in people with relapsing multiple sclerosis (RMS) according to the results of the open-l
- FDA Grants Accelerated Approval to Gene Therapy for the Treatment of AADC Deficiencyhttps://practicalneurology.com/news/fda-grants-accelerated-approval-to-gene-therapy-for-the-treatment-of-aadc-deficiency/2470636/Kebilidi (eladocagene exuparvovec-tneq; PTC Therapeutics, Warren, NJ) has been granted Food and Drug Administration (FDA) approval under the Accelerated Approval pathway for the treatment of adult and pediatric patients with aromatic L-amino acid decarboxylase (AADC) deficiency. Kebilidi is an ad
- Evobrutinib Reduces Relapsing Multiple Sclerosis Disease Activityhttps://practicalneurology.com/news/evobrutinib-reduces-relapsing-multiple-sclerosis-disease-activity/2469723/Post-hoc analysis of data from a phase 2 study (NCT02975349) of evobrutinib (M2951; EMD Serono, Rockland, MA) reduced the volume of slowly expanding MRI lesions in participants with relapsing multiple sclerosis (MS). Slowly expanding l
- Trial Results Show Gene Therapy Causes Improvements in Children with AADC Deficiencyhttps://practicalneurology.com/news/trial-results-show-gene-therapy-causes-improvements-in-children-with-aadc-deficiency/2469710/A new analysis of clinical trial results shows that a novel gene therapy (PTC-AADC; PTC Therapeutics, South Plainfield, NJ) leads to profound improvements in children with aromatic L-amino acid decarboxylase (AADC) deficiency, a rare, intractable, and fatal disorder of the central nervous system.
- Loss of Consciousness With Concussion May Be Associated With Later Increased Disabilityhttps://practicalneurology.com/news/loss-of-consciousness-with-concussion-may-be-associated-with-later-increased-disability/2469600/According to a study published in Neurology, individuals who experienced a concussion where they lost consciousness may be more likely to have some disability or limitations later in life. The participants in the study were asked whether a physical, mental or emotional problem keeps or l
- Vamorolone Has Efficacy for Treating Duchenne Muscular Dystrophy Without Affecting Growthhttps://practicalneurology.com/news/vamorolone-has-efficacy-for-treating-duchenne-muscular-dystrophy-without-affecting-growth/2470013/In the VISION-DMD trial (NCT02760277), children with Duchenne muscular dystrophy (DMD) treated with vamorolone (ReveraGen BioPharma, Rockville, MD), had improved motor function with no negative effects on linear growth or biomarkers of